mRNA therapeutics: Molecular mechanisms, delivery platforms, regulatory frameworks, and equitable global access
Journal of Controlled Release · 2026-07 · 395 · 115019
DOI: 10.1016/j.jconrel.2026.115019 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2026-07. Verfasst von Taruna Ikrar und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Indonesian Food and Drug Authority (BPOM), Jl. Percetakan Negara No. 23, Jakarta Pusat 10560, Indonesia. Hauptthemen laut MEDLINE: RNA, Messenger, Drug Delivery Systems. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 102 Literaturangaben.
Abstract (Originalsprache)
Messenger RNA (mRNA) therapeutics represent a transformative pharmaceutical modality, with three products approved by 2024 across infectious disease and rare metabolic indications. This review critically examines: (i) mRNA molecular architecture including nucleoside modification strategies for immune evasion and platforms beyond conventional mRNA (self-amplifying RNA [saRNA], circular RNA); (ii) lipid nanoparticle (LNP) delivery mechanisms encompassing endosomal escape limitations, selective organ targeting (SORT), and emerging alternative delivery systems including single-component carriers; (iii) the clinical application landscape spanning vaccines, personalised cancer immunotherapy, protein replacement, and CRISPR genome editing; (iv) translational challenges including stability, tissue-targeting, immunogenicity, and manufacturing scalability; and (v) the critically underrepresented dimensions of regulatory science and equitable global access in low- and middle-income countries (LMICs), drawing on Indonesia's BPOM as a policy case study contextualised within the broader LMIC regulatory landscape. Concrete capacity-building recommendations - including establishment of regional mRNA reference standard laboratories, low-cost dsRNA analytical platforms, and harmonised pharmacovigilance systems - are proposed. This review provides a molecularly grounded and policy-relevant synthesis for drug delivery scientists and regulators advancing equitable mRNA therapeutic access.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Indonesian Food and Drug Authority (BPOM), Jl. Percetakan Negara No. 23, Jakarta Pusat 10560, Indonesia.
- The Indonesian Food and Drug Authority (BPOM), Jl. Percetakan Negara No. 23, Jakarta Pusat 10560, Indonesia. Electronic address: alfi.sophian@pom.go.id.
Zitieren
APA
Ikrar, T., Muchsin, W., & Sophian, A. (2026). mRNA therapeutics: Molecular mechanisms, delivery platforms, regulatory frameworks, and equitable global access. Journal of Controlled Release, 395, 115019. https://doi.org/10.1016/j.jconrel.2026.115019
Vancouver
Ikrar T, Muchsin W, Sophian A. mRNA therapeutics: Molecular mechanisms, delivery platforms, regulatory frameworks, and equitable global access. Journal of Controlled Release. 2026;395:115019. doi:10.1016/j.jconrel.2026.115019
BibTeX
@article{Ikrar2026,
author = {Ikrar, Taruna and Muchsin, Wachyudi and Sophian, Alfi},
title = {mRNA therapeutics: Molecular mechanisms, delivery platforms, regulatory frameworks, and equitable global access},
journal = {Journal of Controlled Release},
year = {2026},
volume = {395},
pages = {115019},
doi = {10.1016/j.jconrel.2026.115019}
}
EUVIMED